tbuckley/cabot-search huggingface dataset:
Comparison of second-line treatments in patients with castration-resistant prostate cancer with PSA relapse after or during docetaxel chemotherapy.
Authors: David J. K. P. Pfister, Daniel Porres, Charlotte Piper, Axel S. Merseburger, Theodor Klotz, Axel Heidenreich
Journal: Journal of Clinical Oncology (2012)

243 Background: Docetaxel was the first agent with a proven survival benefit and improved quality of life in patients with castration resistant prostate cancer. Recently there are two new agents, Cabazitaxel (Caba) and Abiraterone Acetate (AA) approved for the second-line treatment in case of progressive disease after Docetaxel. We compared the PSA response and complication rate of these three different second-line treatment options: Caba, AA and Docetaxel Re-Challenge (R-Doc). Methods: The data of 71 patients with progressive disease after/during Docetaxel chemotherapy were analyzed retrospectively. 25 patients with R-Doc, 27 patients with AA and 19 patients with Caba. All patients except two had a PSA-Response or stable disease to primary docetaxel chemotherapy. Mean patient age was 74 years for R-Doc, 71 for AA and 69 for Caba with a mean PSA before initiating treatment of 45 ng/ml, 162ng/ml and 563ng/ml. Results: PSA response rates (&gt;50% regression) were seen in 14 (56%), 8 (38%) and 6 (32%) patients respectively. PSA stabilization was seen in 7 (28%), 2 (9,5%) and 7 (36,8%) patients. Haematologic complications grade &gt;=3 were seen more frequently in R-Doce (32%) and Caba (42%) compared to AA (4%). Cardiovascular complications &gt;= grade 3 were seen in 30% of the patients with AA whereas none of the patients with R-Doc or Caba had cardiovascular grade 3 or 4 side effects. Conclusions: With AA, Caba and the possibility of R-Doc there are compareable treatment options with regard to PSA response rates, even if a stable disease can be seen more frequently in Caba and R-Doc. As the drugs have different side effects the first second line treatment should be considered to the patient’s characteristics and comorbidity in the palliative setting. PSA progression free survival and overall survival data are awaited.
TCR Clonal Evolution in AML Patients in Morphologic Remission Treated with Anti-PD1 Antibody, Nivolumab
Authors: Hongtao Liu, Jae-Hyun Park, Noreen Fulton, Kazuma Kiyotani, Yusuke Nakamura, Olatoyosi Odenike, Wendy Stock
Journal: Blood (2016)
EEC Growth, JAK2 Mutation, PRV-1 Overexpression and X-Chromosome Inactivation Pattern: Predicting Values on Polycythemia Vera Evolution and Risk of Thrombosis in Idiopathic Thrombocytosis.
Authors: Lee-Yung Shih, Ching-Tai Lee, Tung-Liang Lin, Chia-Hui Chang, Chein-Fuang Huang, Po-Nan Wang, Ming-Chung Kuo, Po Dunn, Jin-Hou Wu, Hung Chang, Yii-Jenq Lan, Tzung-Chih Tang
Journal: Blood (2006)
The Relationships Among Exposure to Violence, Psychological Distress, and Gun Carrying Among Male Adolescents Found Guilty of Serious Legal Offenses
Authors: Joan A. Reid, Tara N. Richards, Thomas A. Loughran, Edward P. Mulvey
Journal: Annals of Internal Medicine (2017)

Gun violence and psychological problems are often conflated in public discourse on gun safety. However, few studies have empirically assessed the effect of exposure to violence when exploring the association between gun carrying and psychological distress.To examine the potential effect of exposure to violence on the associations between gun carrying and psychological distress among vulnerable adolescents.Longitudinal cohort study.The Pathways to Desistance study, a study of youths found guilty of a serious criminal offense in Philadelphia County, Pennsylvania, or Maricopa County, Arizona.1170 male youths aged 14 to 19 years who had been found guilty of a serious criminal offense.Youths were assessed at baseline and at four 6-month intervals with regard to gun carrying ("Have you carried a gun?"), psychological distress (Global Severity Index), and exposure to violence (modified version of the Exposure to Violence Inventory).At the bivariate level, gun carrying was consistently associated with higher levels of psychological distress. However, the association between psychological distress and gun carrying diminished or disappeared when exposure to violence was considered. Exposure to violence (as either a victim or a witness) was significantly related to gun carrying at all follow-up assessments, with increased odds of gun carrying ranging from 1.43 to 1.87 with each additional report of exposure to violence.The study sample was limited to justice-involved male youths. Precarrying distress and exposure to violence could not be fully captured because many participants had initiated gun carrying before baseline.In male youths involved in the criminal justice system, the relationship between psychological distress and gun carrying seems to be influenced by exposure to violence (either experiencing or witnessing it). Further study is warranted to explore whether interventions after exposure to violence could reduce gun carrying in this population.None.
Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial
Authors: Yiwey Shieh, Martin Eklund, Lisa Madlensky, Sarah D. Sawyer, Carlie K. Thompson, Allison Stover Fiscalini, Elad Ziv, Laura J. van’t Veer, Laura J. Esserman, Jeffrey A. Tice
Journal: JNCI Journal of the National Cancer Institute (2016)

Ongoing controversy over the optimal approach to breast cancer screening has led to discordant professional society recommendations, particularly in women age 40 to 49 years. One potential solution is risk-based screening, where decisions around the starting age, stopping age, frequency, and modality of screening are based on individual risk to maximize the early detection of aggressive cancers and minimize the harms of screening through optimal resource utilization. We present a novel approach to risk-based screening that integrates clinical risk factors, breast density, a polygenic risk score representing the cumulative effects of genetic variants, and sequencing for moderate- and high-penetrance germline mutations. We demonstrate how thresholds of absolute risk estimates generated by our prediction tools can be used to stratify women into different screening strategies (biennial mammography, annual mammography, annual mammography with adjunctive magnetic resonance imaging, defer screening at this time) while informing the starting age of screening for women age 40 to 49 years. Our risk thresholds and corresponding screening strategies are based on current evidence but need to be tested in clinical trials. The Women Informed to Screen Depending On Measures of risk (WISDOM) Study, a pragmatic, preference-tolerant randomized controlled trial of annual vs personalized screening, will study our proposed approach. WISDOM will evaluate the efficacy, safety, and acceptability of risk-based screening beginning in the fall of 2016. The adaptive design of this trial allows continued refinement of our risk thresholds as the trial progresses, and we discuss areas where we anticipate emerging evidence will impact our approach.
Сучасний стан антибіотикорезистентності Helicobacter pylori та його клінічне значення
Authors: A.V. Naliotov
Journal: GASTROENTEROLOGY (2020)

У статті наведений аналіз літературних даних останніх років із питання формування та поширеності резистентності Helicobacter pylori до різних антибактеріальних препаратів, що використовуються для ерадикації цього мікроорганізму. Обговорені особливості терапевтичних підходів, шляхи подолання стійкості даної інфекції, вибір схем ерадикаційної терапії залежно від рівня резистентності Helicobacter pylori до антибактеріальних препаратів. Особливу увагу приділено питанню про поширеність антибіотикорезистентності Helicobacter pylori в дитячому віці.
Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases
Authors: Lupe G. Salazar, Hailing Lu, Jessica L. Reichow, Jennifer S. Childs, Andrew L. Coveler, Doreen M. Higgins, James Waisman, Kimberly H. Allison, Yushe Dang, Mary L. Disis
Journal: JAMA Oncology (2017)

<h3>Importance</h3> Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. <h3>Objective</h3> To evaluate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound paclitaxel in treatment-refractory breast cancer of the chest wall. <h3>Design, Setting, and Particpants</h3> A single arm phase 2 clinical trial of 15 patients with breast cancer previously treated in an academic medical center setting between 2009 and 2012 for chest wall disease that had recurred. <h3>Interventions</h3> Imiquimod cream, 5%, was applied topically to a designated target lesion once per day for 4 consecutive days on days 1 through 4, 8 through 11, 15 through 18, and 22 through 25 of a 28-day cycle, for 12 weeks. Albumin bound paclitaxel, 100 mg/m<sup>2</sup>, was given intravenously on days 1, 8, and 15, and repeated every 28 days over the 12-week period. <h3>Main Outcomes and Measures</h3> The primary endpoint was safety and ORR. Secondary endpoints included the generation of tumor-infiltrating lymphocytes and modulation of immune cell populations. <h3>Results</h3> The median age at baseline of the 15 study participants was 54 years (range, 46-92 years). Fourteen patients were evaluable. Combination therapy was associated with low-grade toxic effects. Of 358 adverse events 330 (92%) were grades 1 and 2. Five (36%) patients achieved a compete response and another 5 (36%) were partial responders for an overall response rate of 72% (10 of 14). The response duration was limited. Pretreatment levels of programmed death-1 (PD-1)+ peripheral blood T cells (PD-1+ cluster of differentiation [CD]4+; 95% CI, 2.68-6.63;<i>P</i> &lt; .001 and PD-1+CD8+; 95% CI, 1.13-8.35;<i>P</i> = .01) and monocytic myeloid derived suppressor cells (mMDSC) (95% CI, 3.62-12.74;<i>P</i> = .001) greater than controls predicted suboptimal clinical response. <h3>Conclusions and Relevance</h3> Chemoimmunomodulation with a TLR-7 agonist and albumin bound paclitaxel is effective in inducing disease regression in treatment-refractory breast cancer chest wall metastases but responses are short-lived. Preexisting levels of cells indicating either T-cell exhaustion or systemic immunosuppression may be markers of selection for responsive patients. <h3>Trial Registration</h3> clinicaltrials.gov Identifier:NCT00821964
Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC).
Authors: Thai Huu Ho, Federico A. Monzon, Anh Hoang, Pheroze Tamboli, Kyle A. Furge, Karl Dykema, David Petillo, Bin Tean Teh, Nizar M. Tannir, Mien-Chie Hung, Eric Jonasch
Journal: Journal of Clinical Oncology (2012)

368 Background: Although the von Hippel-Lindau (VHL) tumor suppressor gene is mutated in 60% of ccRCC, deletion of VHL in mice is insufficient for tumorigenesis. Sequencing of ccRCC tumors identified loss of function mutations in SETD2, a histone H3 lysine 36 (H3K36) trimethyltransferase. However it is unclear whether histone modifications are misregulated in RCC. We hypothesize that loss of SETD2 methyltransferase activity decreases H3K36 trimethylation (H3K36Me3) in ccRCC, and contributes to the cancer phenotype. Methods: To determine if loss of SETD2 protein expression alters H3K36Me3, SETD2 siRNA oligonucleotides were transfected into HEK293 (human embryonic kidney) cells and H3K36Me3 was analyzed by Western blot. To establish frequency of SETD2 loss of heterozygosity (LOH), genomic DNA was isolated from 51 VHL deficient ccRCC specimens and analyzed with Affymetrix GeneChip Mapping 250K Nsp single-nucleotide polymorphism (SNP) arrays. To evaluate alterations of histone modifications in metastatic advanced ccRCC, H3K36Me3 immunohistochemical (IHC) staining was quantitated on tissue microarrays (TMAs) representing 28 paired ccRCC specimens with unaffected kidney parenchyma controls and 40 metastases. Results: SETD2 siRNA decreases H3K36Me3 (&gt;50%) compared to scrambled controls. Using SNP arrays, LOH at chromosome 3p (location of VHL and SETD2 genes) was detected in &gt;90% of the tested ccRCC tumors. IHC reveals a 27.4% and 52.0% decrease in H3K36Me3 positive nuclei in primary ccRCC and metastases, respectively, when compared to matched adjacent unaffected kidney tissue (P value &lt; 0.0001). Conclusions: SETD2 siRNA decreases H3K36Me3 indicating that SETD2 is a non-redundant H3K36 methyltransferase. LOH of VHL and SETD2 occurs in &gt;90% of tested ccRCC tumors. H3K36Me3 is decreased in primary ccRCC and even more in metastases, suggesting that SETD2 methyltransferase activity is progressively misregulated in RCC. Loss of SETD2 methyltransferase activity may cooperate with VHL silencing to promote tumorigenesis. Future studies will focus on how SETD2 contributes to tumorigenesis and on determining the prognostic and predictive impact of SETD2 phenotypic changes in patients with ccRCC.
Secukinumab for Acrodermatitis Continua of Hallopeau
Authors: David Muggli, Julia-Tatjana Maul, Florian Anzengruber, Myriam Wyss Fopp, Alexander A. Navarini
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas
Authors: Nancy H. Liu, Gail L. Daumit, Tarun Dua, Ralph Aquila, Fiona Charlson, Pim Cuijpers, Benjamin Druss, Kenn Dudek, Melvyn Freeman, Chiyo Fujii, Wolfgang Gaebel, Ulrich Hegerl, Itzhak Levav, Thomas Munk Laursen, Hong Ma, Mario Maj, Maria Elena Medina‐Mora, Merete Nordentoft, Dorairaj Prabhakaran, Karen Pratt, Martin Prince, Thara Rangaswamy, David Shiers, Ezra Susser, Graham Thornicroft, Kristian Wahlbeck, Abe Fekadu Wassie, Harvey Whiteford, Shekhar Saxena
Journal: World Psychiatry (2017)

Excess mortality in persons with severe mental disorders (SMD) is a major public health challenge that warrants action. The number and scope of truly tested interventions in this area remain limited, and strategies for implementation and scaling up of programmes with a strong evidence base are scarce. Furthermore, the majority of available interventions focus on a single or an otherwise limited number of risk factors. Here we present a multilevel model highlighting risk factors for excess mortality in persons with SMD at the individual, health system and socio‐environmental levels. Informed by that model, we describe a comprehensive framework that may be useful for designing, implementing and evaluating interventions and programmes to reduce excess mortality in persons with SMD. This framework includes individual‐focused, health system‐focused, and community level and policy‐focused interventions. Incorporating lessons learned from the multilevel model of risk and the comprehensive intervention framework, we identify priorities for clinical practice, policy and research agendas.
Differentially Expressed and Prognostically Significant Lincrnas May Impact Immune System and Tumor Progression in Multiple Myeloma (MM)
Authors: Mehmet K Samur, Annamaria Gulla, Alice Cleynen, Florence Magrangeas, Stephane Minvielle, Kenneth C Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi
Journal: Blood (2015)
Fto Plays an Oncogenic Role in Acute Myeloid Leukemia As a N6-Methyladenosine RNA Demethylase
Authors: Rui Su, Zejuan Li, Hengyou Weng, Xiaocheng Weng, Zhixiang Zuo, Chenying Li, Huilin Huang, Chao Hu, Xi Qin, Lichuan Tang, Yungui Wang, Gia-Ming Hong, Hao Huang, Xiao Wang, Ping Chen, Sandeep Gurbuxani, Stephen Arnovitz, Yuanyuan Li, Shenglai Li, Jennifer Strong, Mary Elizabeth Neilly, Richard A. Larson, Xi Jiang, Pumin Zhang, Jie Jin, Chuan He, Jianjun Chen
Journal: Blood (2016)
Dasatinib (BMS-354825): A Multi-Targeted Kinase Inhibitor with Activity Against Multiple Myeloma.
Authors: Qingwei Deng, Nicholas Mitsiades, Joseph Negri, Zhaoqin Wen, Melissa Rooney, Teru Hideshima, Dharminder Chauhan, Nikhil C. Munshi, Paul G. Richardson, Francis Y. Lee, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2005)
Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT)
Authors: Hong Liu, Theresa Hahn, Gregory Wilding, Adrienne Groman, Barbara Bambach, Meghan Higman, Maureen Ross, George L. Chen, Philip L. McCarthy
Journal: Blood (2011)
A Novel Pre-Clinical Xenograft Model to Study TSLP-CRLF2 Interactions in B-ALL
Authors: Ruijun Su, Olivia Francis, Shannalee Martinez, Terrence Bennett, Ineavely Baez, Terry-Ann Milford, Xiao-Bing Zhang, Christopher L. Morris, Sinsa Dovat, Kimberly J Payne
Journal: Blood (2012)
Challenges in Assessing Cardiovascular Mortality Among Hispanic/Latino Groups in the United States
Authors: Martha L. Daviglus, Amber Pirzada, Jeremiah Stamler
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Improvement in Clinical Benefit Parameters with Pomalidomide (POM) in Combination with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Results From a Phase 2 Study
Authors: Sagar Lonial, Rachid Baz, Nizar J. Bahlis, Christine I. Chen, Kenneth C. Anderson, Min Chen, Mohamed Zaki, Paul G. Richardson
Journal: Blood (2012)
A Bio-Integrative Approach Identifies an Inflammatory Signature in Chronic Myeloid Leukemia (CML) Stem Cells That Is Highly Perturbed in CML Blast Crisis and Involves REL transcription Factor
Authors: Christophe Desterke, Ludovic Marie-Sainte, Amine Sbitti, Ali Naama, Annelise Bennaceur-Griscelli, Ali G Turhan, Ivan Sloma
Journal: Blood (2015)
A call to capture fatalities in consensus statements for sports injury/illness surveillance
Authors: Lauren V Fortington, Kristen L Kucera, Caroline F Finch
Journal: British Journal of Sports Medicine (2017)

Deaths are considered to be rare in sport, but detailed information and specific fatality rates for different sport settings are limited owing to a paucity of data. Most research originates in the USA,1 2 and it has identified sudden cardiac arrest, traumatic injuries to the head/neck, exertional heat stroke, hyponatremia and asthma2 as the leading causes. Put simply, in sport, death can result from direct (eg, acute traumatic injuries) or indirect (eg, underlying illness/condition) causes, with external/environmental factors also implicated in some events.3 An understanding of the people that are most at risk and the leading causes of deaths in sporting environments, is a crucial first step toward implementing appropriate emergency management plans to prevent fatalities.

The value and importance of surveillance to guide management and prevention of fatalities is well established, including in sport where data-driven changes have led to a reduction in …
The significance of irregularly contracted cells and hemighosts in sickle cell disease
Authors: Wenchee Siow, Francis Matthey, Barbara J. Bain
Journal: American Journal of Hematology (2017)

The presence of considerable numbers of irregularly contracted cells and hemighosts in sickle cell disease may serve as a warning of severe sickle crisis with significant hypoxia. We report two cases that demonstrate this association. The first patient was a 52-year-old woman with sickle cell/β0 thalassemia who presented with generalised bone pain. She was given intravenous fluids, antibiotics and analgesia but, despite treatment, developed respiratory failure with a PO2 of 7.0 kPa. Her blood count showed: white cell count (WBC) 10.0 × 109/L, hemoglobin concentration (Hb) 72 g/L, MCV 63.9 fl and platelets 257 ×109/L. In addition to the usual features of sickle cell disease, her blood film showed hemighost cells in which the hemoglobin was retracted to one side of the erythrocyte (top left). This phenomenon was also observed in cells showing evidence of hemoglobin polymerization—cells with pointed ends and sometimes a gentle curve (top right). She declined continuous positive airway pressure and was commenced on high flow oxygen by nasal cannula, to which she responded well. The second patient was a young man with sickle cell anemia. He suffered a cardiac arrest and became severely hypoxic. His blood count then showed: WBC 26.5 × 109/L, Hb 101 g/L, MCV 88.7 fl and platelet count 110 × 109/L. His blood film showed numerous hemighosts with hemoglobin retracted to one side of the cell or to both ends of an elongated cell (bottom left). In addition, there were irregularly contracted cells, some of which were somewhat angular, suggesting that polymerization was occurring (bottom right). Irregularly contracted cells and hemighosts can be a warning sign of severe hypoxia and worsening crisis in patients with sickle cell disease. This blood film observation reflects the increased percentage of dense cells demonstrable on density gradient analysis in patients with sickle cell crisis.1 Nothing to report